Profil
Ashleigh Barreto is currently the Head of Investor Relations and Corporate Communications at Viracta Therapeutics, Inc. Prior to this, she worked as the Director of Communications and Investor Relations at Adamas Pharmaceuticals LLC and as the Head of Investor and Media Relations at XOMA Corp.
Aktive Positionen von Ashleigh Barreto
| Unternehmen | Position | Beginn |
|---|---|---|
| VIRACTA THERAPEUTICS, INC. | Investor Relations Contact | 01.10.2021 |
Ehemalige bekannte Positionen von Ashleigh Barreto
| Unternehmen | Position | Ende |
|---|---|---|
| ADAMAS PHARMACEUTICALS, INC. | Investor Relations Contact | 01.12.2018 |
| XOMA CORPORATION | Investor Relations Contact | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| XOMA CORPORATION | Health Technology |
| VIRACTA THERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Adamas Pharmaceuticals LLC
 Adamas Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA. | Health Technology |
